A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)
Latest Information Update: 30 May 2024
At a glance
- Drugs Calcifediol (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Acronyms REsCue
- Sponsors OPKO Health
Most Recent Events
- 24 Feb 2022 According to OPKO Health media release, the topline data from this trial is available on medRxiv and this manuscript is currently under review for publication in a peer-reviewed medical journal.
- 23 Dec 2021 Preliminary topline results published in the OPKO Health media release.
- 14 Oct 2021 Status changed from active, no longer recruiting to completed.